MHC class i expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome

International Journal of Cancer

Volumn 132, Issue 1, 2013, Pages 72-81

  Näsman, Anders ^a   Andersson, Emilia ^a   Nordfors, Cecilia ^a   Grün, Nathalie ^a   Johansson, Hemming ^a   Munck Wikland, Eva ^a   Massucci, Giuseppe ^a   Dalianis, Tina ^a   Ramqvist, Torbjörn ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

head and neck cancer; hla class I; human papillomavirus; oropharyngeal squamous cell carcinoma; prognosis; tonsillar squamous cell carcinoma; treatment

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FORMALDEHYDE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA E ANTIGEN; HLA G ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PARAFFIN; VIRUS DNA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CELL MEMBRANE; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TONSIL CARCINOMA; TONSILLAR SQUAMOUS CELL CARCINOMA; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; GENES, MHC CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TONSILLAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868205836     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27635     Document Type: Article

References (43)

1. Ramqvist T, Dalianis T,. Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 2010; 16: 1671-7.
2. Frisch M, Hjalgrim H, Jaeger AB, et al. Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 2000; 11: 489-95.
3. Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125: 362-6.
4. Shiboski CH, Schmidt BL, Jordan RC,. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 2005; 103: 1843-9.
5. IARC, Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90: 1-636.
6. Leemans CR, Braakhuis BJ, Brakenhoff RH,. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11: 9-22.
7. Lindquist D, Romanitan M, Hammarstedt L, et al. Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 2007; 1: 350-5.
8. Ferreira MB, De Souza JA, Cohen EE,. Role of molecular markers in the management of head and neck cancers. Curr Opin Oncol 2011; 23: 259-64.
9. Ragin CC, Taioli E,. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121: 1813-20.
10. Licitra L, Bernier J, Grandi C, et al. Cancer of the oropharynx. Crit Rev Oncol Hematol 2002; 41: 107-22.
11. Zackrisson B, Nilsson P, Kjellen E, et al. Two-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinomaa-the ARTSCAN study. Radiother Oncol 2011; 100: 41-8.
12. Campoli M, Ferrone S,. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008; 27: 5869-85.
13. Rodriguez T, Aptsiauri N, Mendez R, et al. Different mechanisms can lead to the same altered HLA class I phenotype in tumors. Tissue Antigens 2007; 69 (Suppl 1): 259-63.
14. Pages F, Kroemer G,. Prognostic impact of anticancer immune responses: an introduction. Semin Immunopathol 2011; 33: 317-9.
15. Bandoh N, Ogino T, Katayama A, et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep 2010; 23: 933-9.
16. Feenstra M, Veltkamp M, van Kuik J, et al. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 1999; 54: 235-45.
17. Maleno I, Lopez-Nevot MA, Cabrera T, et al. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 2002; 51: 389-96.
18. Meissner M, Reichert TE, Kunkel M, et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005; 11: 2552-60.
19. Ogino T, Shigyo H, Ishii H, et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006; 66: 9281-9.
20. de Kruijf EM, van Nes JG, Sajet A, et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 2010; 16: 1272-80.
21. Bottley G, Watherston OG, Hiew YL, et al. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 2008; 27: 1794-9.
22. Gruener M, Bravo IG, Momburg F, et al. The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells. Virol J 2007; 4: 116.
23. Campo MS, Graham SV, Cortese MS, et al. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 2010; 407: 137-42.
24. Li H, Ou X, Xiong J, et al. HPV16E7 mediates HADC chromatin repression and downregulation of MHC class I genes in HPV16 tumorigenic cells through interaction with an MHC class I promoter. Biochem Biophys Res Commun 2006; 349: 1315-21.
25. Amiot L, Ferrone S, Grosse-Wilde H, et al. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci 2011; 68: 417-31.
26. Yie SM, Yang H, Ye SR, et al. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol 2007; 128: 1002-9.
27. Yie SM, Yang H, Ye SR, et al. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 2007; 58: 267-74.
28. Yie SM, Yang H, Ye SR, et al. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol 2007; 14: 2721-9.
29. Carosella ED, Gregori S, Rouas-Freiss N, et al. The role of HLA-G in immunity and hematopoiesis. Cell Mol Life Sci 2011; 68: 353-68.
30. Marin R, Ruiz-Cabello F, Pedrinaci S, et al. Analysis of HLA-E expression in human tumors. Immunogenetics 2003; 54: 767-75.
31. Goncalves MA, Le Discorde M, Simoes RT, et al. Classical and non-classical HLA molecules and p16(INK4a) expression in precursors lesions and invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2008; 141: 70-4.
32. Tomasec P, Braud VM, Rickards C, et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000; 287: 1031.
33. Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006; 119: 2620-3.
34. Seitz C, Uchanska-Ziegler B, Zank A, et al. The monoclonal antibody HCA2 recognises a broadly shared epitope on selected classical as well as several non-classical HLA class I molecules. Mol Immunol 1998; 35: 819-27.
35. Sernee MF, Ploegh HL, Schust DJ,. Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 1998; 35: 177-88.
36. Hutter H, Hammer A, Blaschitz A, et al. Expression of HLA class I molecules in human first trimester and term placenta trophoblast. Cell Tissue Res 1996; 286: 439-47.
37. Perosa F, Luccarelli G, Prete M, et al. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003; 171: 1918-26.
38. Tang Q, Zhang J, Qi B, et al. Downregulation of HLA class I molecules in primary oral squamous cell carcinomas and cell lines. Arch Med Res 2009; 40: 256-63.
39. Vertuani S, Triulzi C, Roos AK, et al. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 2009; 58: 653-64.
40. Jordanova ES, Gorter A, Ayachi O, et al. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 2008; 14: 2028-35.
41. Mehta AM, Jordanova ES, Kenter GG, et al. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 2008; 57: 197-206.
42. Madjd Z, Spendlove I, Pinder SE, et al. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005; 117: 248-55.
43. Watson NF, Ramage JM, Madjd Z, et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006; 118: 6-10.